Medications

FDA approves Xdemvy for Demodex blepharitis

The U.S. Food and Drug Administration has approved Xdemvy (lotilaner ophthalmic solution) 0.25 percent for the treatment of Demodex blepharitis, caused by Demodex mites.

Oncology & Cancer

Models can predict breast cancer-related lymphedema

Preoperative and postoperative models are highly accurate for predicting breast cancer-related lymphedema (BCRL), according to a study published online July 12 in JAMA Surgery.

Medical economics

Variation noted in physician turnover rates from 2010 to 2020

Physician turnover rates increased from 2010 to 2014, then stabilized through 2017, with no indication of an increase during the first three quarters of 2020, coincident with COVID-19, according to a study published online ...

page 10 from 40